Allergy Therapeutics (AGY)

 

Latest News

Block Listing Application

RNS Number: 0383X Allergy Therapeutics PLC 21 November 2017 21 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Block Listing Application Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that an application has been made to the London Stoc...

Allergy Therapeutics to Present at Jefferies 2017

RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...

Director/PDMR Shareholding

RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...

Director/PDMR Shareholding

RNS Number: 8006V Allergy Therapeutics PLC 07 November 2017 07 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Grant of Options under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance c...

All News

DateHeadlineSource
27-09-13Allergy Therapeutics appoints adviser StockMarketWire
27-09-13Change of AdviserRNS
19-09-13Holding(s) in CompanyRNS
16-09-13Allergy Therapeutics improves market shareStockMarketWire
16-09-13Final ResultsRNS
15-08-13Allergy Therapeutics schedules FY results StockMarketWire
15-08-13Notice of results and shareholder updateRNS
03-06-13Holding(s) in CompanyRNS
15-05-13Grant of OptionsRNS
08-05-13Holding(s) in CompanyRNS
08-05-13Holding(s) in CompanyRNS
25-03-13Half Yearly ReportRNS
11-03-13Allergy Therapeutics granted US patent StockMarketWire
11-03-13US patent grantedRNS
11-03-13Notice of results and shareholder updateRNS
01-02-13Total Voting RightsRNS
22-01-13Exercise of OptionsRNS
28-12-12Total Voting RightsRNS
27-12-12Update on Lincoln Medical FinalRNS
19-12-12Grant of OptionsRNS
10-12-12Director/PDMR ShareholdingRNS
05-12-12Total Voting RightsRNS
04-12-12Exercise of OptionsRNS
30-11-12Total Voting RightsRNS
21-11-12Holding(s) in CompanyRNS
20-11-12Exercise of OptionsRNS
14-11-12Result of AGMRNS
09-11-12Director/PDMR ShareholdingRNS
16-10-12Annual Financial ReportRNS
04-10-12Holding(s) in CompanyRNS
17-09-12Final ResultsRNS
30-08-12Notice of results and shareholder updateRNS
03-08-12Markets: FTSE 100 climbs higher on FridayInteractive Investor
03-08-12FDA Clinical Hold LiftedRNS
31-05-12Holding(s) in CompanyRNS
23-05-12Voluntary recall of Anapen by Lincoln MedicalRNS
17-05-12Holding(s) in CompanyRNS
17-05-12Holding(s) in CompanyRNS
16-05-12Total Voting RightsRNS
02-05-12Board AppointmentRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account